CN105125504A - Composition granules of blood lipid-lowering drug pitavastatin calcium - Google Patents
Composition granules of blood lipid-lowering drug pitavastatin calcium Download PDFInfo
- Publication number
- CN105125504A CN105125504A CN201510589951.1A CN201510589951A CN105125504A CN 105125504 A CN105125504 A CN 105125504A CN 201510589951 A CN201510589951 A CN 201510589951A CN 105125504 A CN105125504 A CN 105125504A
- Authority
- CN
- China
- Prior art keywords
- pitavastatin calcium
- weight
- granule
- weight portion
- blood lipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates composition granules of a blood lipid-lowering drug pitavastatin calcium and belongs to the technical field of medicines. The composition granules are prepared from pitavastatin calcium, mannitol, sucrose, tert-butyl-4-hydroxyanisole, sodium alginate, purified water and silicon dioxide. The pitavastatin calcium is a new crystal form compound, and an X-ray powder diffraction pattern obtained by measuring by Cu-K alpha rays is shown as a figure 1; the pitavastatin calcium is different from pitavastatin calcium reported in the prior art; an experimental research shows that the granules prepared by the compound have the function of remarkably improving the effect of inhibiting the activity of HMG-CoA reductase of the pitavastatin calcium while the stability is improved, so that the blood lipid lowering effect is remarkably improved.
Description
Technical field
The invention belongs to medical art, relate to a kind of blood lipid-lowering medicine Pitavastatin Calcium composition granule.
Background technology
Pitavastatin Calcium is first complete synthesis HMG-CoA reductase inhibitor of Nissan Chemical company and Kowa company Ltd's exploitation, be the another potent stanin fat-reducing medicament after atorvastatin and Rosuvastatin, be mainly used in treating hypercholesterolemia, familial hypercholesterolemia.In November, 1999 at Japan registration, and on July 17th, 2003 first in Japan's approval listing, follow-up in succession in Korea S, Thailand, China and U.S.A listing.Abroad be described as " superstatin " with the powerful blood fat reducing effect shown in its clinical trial.In the face of the raising day by day of hyperlipidemia sickness rate, we need to find medicine more efficiently.
The invention provides a kind of Pitavastatin Calcium crystal compound, it is a kind of Pitavastatin Calcium being different from prior art report, find that the granule that this compound is made has the effect significantly improving Pitavastatin Calcium and suppress HMG-CoA reductase activity while improving stability by experimental study, thus significantly improve its lipid-lowering effect.
Summary of the invention
Goal of the invention of the present invention is to provide a kind of blood lipid-lowering medicine Pitavastatin Calcium composition granule.
In order to complete object of the present invention, the technical scheme of employing is:
The present invention relates to a kind of blood lipid-lowering medicine Pitavastatin Calcium composition granule, described composition granule is made up of Pitavastatin Calcium, mannitol, sucrose, tertiary butyl-4-hydroxy methyl phenyl ethers anisole, sodium alginate, purified water, silicon dioxide; Described Pitavastatin Calcium is crystal, and the X-ray powder diffraction pattern that the measurement of use Cu-K alpha ray obtains as shown in Figure 1.
First optimal technical scheme of the present invention is: with parts by weight, and described composition granule is made up of the Pitavastatin Calcium of 0.2 weight portion, the mannitol of 4.3-4.7 weight portion, the sucrose of 14.2-14.6 weight portion, the tertiary butyl-4-hydroxy methyl phenyl ethers anisole of 1.3-1.7 weight portion, the sodium alginate of 1.3-1.7 weight portion, the purified water of 4.3-4.7 weight portion, the silicon dioxide of 0.2-0.4 weight portion.
Second optimal technical scheme of the present invention is: with parts by weight, and described composition granule is made up of the Pitavastatin Calcium of 0.2 weight portion, the mannitol of 4.5 weight portions, the sucrose of 14.4 weight portions, the tertiary butyl-4-hydroxy methyl phenyl ethers anisole of 1.5 weight portions, the sodium alginate of 1.5 weight portions, the purified water of 4.5 weight portions, the silicon dioxide of 0.3 weight portion.
3rd optimal technical scheme of the present invention is: the preparation method of described composition granule comprises the following steps:
1) weigh according to technology preparation amount;
2) Feedstock treating: by raw material pulverizing 100 mesh sieve;
3) premix: select three-dimensional motion mixer, the mode that the Pitavastatin Calcium of recipe quantity and mannitol equivalent are progressively increased mixed, mixing velocity 12r/min, mixes 5min at every turn;
4) mixing granulation: the sucrose of Pitavastatin Calcium complete for premix and mannitol and recipe quantity, tertiary butyl-4-hydroxy methyl phenyl ethers anisole, sodium alginate are added in wet mixing pelletizer, open stirring motor and be dry mixed 10 minutes, add appropriate purified water, wet mixing cutting 120-150 soft material second, selects 18 order nylon wires to be arranged in oscillating granulator and granulates;
5) drying and screening: regulate boiling drier inlet temperature 50-55 DEG C, wet granular is placed in boiling drier and carries out drying, be dried to moisture < 3.0%, granule shaking screen after drying is sieved the granule got between 16 order-30 orders;
6) always mix: the silicon dioxide of the dry granule after granulate and recipe quantity is joined in mixer, mixing velocity 12r/min, open mixer and mix 30 minutes;
7) pack: granule is joined particles packing machine intermediate package, control content uniformity and meet inner quality standard.
4th optimal technical scheme of the present invention is: the preparation method of the crystal of described Pitavastatin Calcium comprises the following steps:
(1) ground by Pitavastatin Calcium crude product, cross 60 mesh sieves, then joining volume is in the methanol of 6 times of Pitavastatin Calcium weight, and 130 revs/min are stirred 10 minutes;
Add the methanol that volume is 4 times of Pitavastatin Calcium weight under (2) 90 revs/min of stirrings, be warming up to 45 DEG C simultaneously;
(3) after solution adds, leave standstill 4 hours, the volume dripping 0 DEG C under 150 revs/min of conditions stirred is 8 times of ether of Pitavastatin Calcium weight, the mixed solution of chloroform, and the volume ratio of ether, chloroform is at the uniform velocity dropwise in 3:2,2h;
(4) be cooled to-5 DEG C after being added dropwise to complete, continue to stir 2h under the stir speed (S.S.) of 110 revs/min, leave standstill 1h crystallize out, filter, washing, vacuum drying obtains Pitavastatin Calcium crystal.
Below technical scheme of the present invention is made further explanation:
The polymorphism of solid chemical is the natural phenomena that a kind of general material exists, this phenomenon refers to that a kind of solid chemical can exist 2 kinds or two or more crystal form state, be also called the polymorphic state of material, the polymorphic state of material is also referred to as " allomorphism " phenomenon.Although its chemical nature of allomorphous solid matter is identical, its physicochemical property may be different.For " allomorphism medicine " that physicochemical property is different, also can show the curative effect of different disease preventing and treating clinically, directly affect application and the clinical effectiveness of medicine.
The present inventor obtains a kind of Pitavastatin Calcium novel crystal forms structure being different from prior art through a large amount of tests, and by test, show that the granule that this crystal compound is made has the effect significantly improving Pitavastatin Calcium and suppress HMG-CoA reductase activity while improving stability, thus significantly improve its lipid-lowering effect.
Accompanying drawing explanation
Fig. 1 is the X-ray powder diffraction that the Pitavastatin Calcium crystal of the embodiment of the present invention 1 preparation uses the measurement of Cu-K alpha ray to obtain.
Detailed description of the invention
Below by specific embodiment, summary of the invention of the present invention is described in further detail, but does not therefore limit content of the present invention.
embodiment 1:the preparation of Pitavastatin Calcium crystal
(1) ground by Pitavastatin Calcium crude product, cross 60 mesh sieves, then joining volume is in the methanol of 6 times of Pitavastatin Calcium weight, and 130 revs/min are stirred 10 minutes;
Add the methanol that volume is 4 times of Pitavastatin Calcium weight under (2) 90 revs/min of stirrings, be warming up to 45 DEG C simultaneously;
(3) after solution adds, leave standstill 4 hours, the volume dripping 0 DEG C under 150 revs/min of conditions stirred is 8 times of ether of Pitavastatin Calcium weight, the mixed solution of chloroform, and the volume ratio of ether, chloroform is at the uniform velocity dropwise in 3:2,2h;
(4) be cooled to-5 DEG C after being added dropwise to complete, continue to stir 2h under the stir speed (S.S.) of 110 revs/min, leave standstill 1h crystallize out, filter, washing, vacuum drying obtains Pitavastatin Calcium crystal.
As shown in Figure 1, its purity of high-performance liquid chromatogram determination is 99.9% to the X-ray powder diffraction pattern that the Pitavastatin Calcium crystal prepared uses the measurement of Cu-K alpha ray to obtain.
embodiment 2:the preparation of Pitavastatin Calcium granule
Prescription: with parts by weight, the Pitavastatin Calcium 0.2 part that embodiment 1 is obtained, 4.3 parts, mannitol, sucrose 14.2 parts, tertiary butyl-4-hydroxy methyl phenyl ethers anisole 1.3 parts, sodium alginate 1.3 parts, purified water 4.3 parts, silicon dioxide 0.2 part.
Preparation method:
1) weigh according to technology preparation amount;
2) Feedstock treating: by raw material pulverizing 100 mesh sieve;
3) premix: select three-dimensional motion mixer, the mode that the Pitavastatin Calcium of recipe quantity and mannitol equivalent are progressively increased mixed, mixing velocity 12r/min, mixes 5min at every turn;
4) mixing granulation: the sucrose of Pitavastatin Calcium complete for premix and mannitol and recipe quantity, tertiary butyl-4-hydroxy methyl phenyl ethers anisole, sodium alginate are added in wet mixing pelletizer, open stirring motor and be dry mixed 10 minutes, add appropriate purified water, wet mixing cutting 120-150 soft material second, selects 18 order nylon wires to be arranged in oscillating granulator and granulates;
5) drying and screening: regulate boiling drier inlet temperature 50-55 DEG C, wet granular is placed in boiling drier and carries out drying, be dried to moisture < 3.0%, granule shaking screen after drying is sieved the granule got between 16 order-30 orders;
6) always mix: the silicon dioxide of the dry granule after granulate and recipe quantity is joined in mixer, mixing velocity 12r/min, open mixer and mix 30 minutes;
7) pack: granule is joined particles packing machine intermediate package, control content uniformity and meet inner quality standard.
embodiment 3:the preparation of Pitavastatin Calcium granule
Prescription: with parts by weight, the Pitavastatin Calcium 0.2 part that embodiment 1 is obtained, 4.5 parts, mannitol, sucrose 14.4 parts, tertiary butyl-4-hydroxy methyl phenyl ethers anisole 1.5 parts, sodium alginate 1.5 parts, purified water 4.5 parts, silicon dioxide 0.3 part.
Preparation method:
1) weigh according to technology preparation amount;
2) Feedstock treating: by raw material pulverizing 100 mesh sieve;
3) premix: select three-dimensional motion mixer, the mode that the Pitavastatin Calcium of recipe quantity and mannitol equivalent are progressively increased mixed, mixing velocity 12r/min, mixes 5min at every turn;
4) mixing granulation: the sucrose of Pitavastatin Calcium complete for premix and mannitol and recipe quantity, tertiary butyl-4-hydroxy methyl phenyl ethers anisole, sodium alginate are added in wet mixing pelletizer, open stirring motor and be dry mixed 10 minutes, add appropriate purified water, wet mixing cutting 120-150 soft material second, selects 18 order nylon wires to be arranged in oscillating granulator and granulates;
5) drying and screening: regulate boiling drier inlet temperature 50-55 DEG C, wet granular is placed in boiling drier and carries out drying, be dried to moisture < 3.0%, granule shaking screen after drying is sieved the granule got between 16 order-30 orders;
6) always mix: the silicon dioxide of the dry granule after granulate and recipe quantity is joined in mixer, mixing velocity 12r/min, open mixer and mix 30 minutes;
7) pack: granule is joined particles packing machine intermediate package, control content uniformity and meet inner quality standard.
embodiment 4:the preparation of Pitavastatin Calcium granule
Prescription: with parts by weight, the Pitavastatin Calcium 0.2 part that embodiment 1 is obtained, 4.7 parts, mannitol, sucrose 14.6 parts, tertiary butyl-4-hydroxy methyl phenyl ethers anisole 1.7 parts, sodium alginate 1.7 parts, purified water 4.7 parts, silicon dioxide 0.4 part.
Preparation method:
1) weigh according to technology preparation amount;
2) Feedstock treating: by raw material pulverizing 100 mesh sieve;
3) premix: select three-dimensional motion mixer, the mode that the Pitavastatin Calcium of recipe quantity and mannitol equivalent are progressively increased mixed, mixing velocity 12r/min, mixes 5min at every turn;
4) mixing granulation: the sucrose of Pitavastatin Calcium complete for premix and mannitol and recipe quantity, tertiary butyl-4-hydroxy methyl phenyl ethers anisole, sodium alginate are added in wet mixing pelletizer, open stirring motor and be dry mixed 10 minutes, add appropriate purified water, wet mixing cutting 120-150 soft material second, selects 18 order nylon wires to be arranged in oscillating granulator and granulates;
5) drying and screening: regulate boiling drier inlet temperature 50-55 DEG C, wet granular is placed in boiling drier and carries out drying, be dried to moisture < 3.0%, granule shaking screen after drying is sieved the granule got between 16 order-30 orders;
6) always mix: the silicon dioxide of the dry granule after granulate and recipe quantity is joined in mixer, mixing velocity 12r/min, open mixer and mix 30 minutes;
7) pack: granule is joined particles packing machine intermediate package, control content uniformity and meet inner quality standard.
test example 1:
Pitavastatin Calcium granule prepared by Example 2-4, detects related substance (see table 1), vitro inhibition HMG-CoA reductase activity (see table 2) respectively.
1, animal strains, body weight and sex
Sprague-Dawley rat, 180-220g, male
2, hyperlipemia model of rats preparation
Hyperlipemia model of rats adopts high lipid food to cause hyperlipemia method.High lipid food formula is as follows: normal feedstuff 86.3%, cholesterol 3%, Adeps Sus domestica 10%, methylthiouracil 0.2%, Fel Sus domestica salt 0.5%, ensures l composition mix homogeneously, continuous 2 weeks.High lipid food is given every other day during administration.
3, vitro inhibition HMG-CoA reductase activity test
With sheet power of going on the market clear for positive control, not adding any inhibitor is negative control, simultaneously with without HMG-CoA and unrestraint agent for blank.
3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) is under HMG-CoA reductase catalysis, consume two molecule reduced form NADPs (NADPH) and generate 3-methyl-3,5-dihydroxy valeric acid and nicotinamide adenine dinucleotide (NADP).NADPH has absorption maximum at ultraviolet 340nm, and NADP at this wavelength without absorption, measure this system and can obtain in the speed that 340nm ultraviolet absorption value declines the speed that this reduction reaction carries out, after adding inhibitor, the rejection ability of inhibitor to enzyme can be calculated by the change of ultraviolet absorption value.The present composition is measured to the inhibit activities of HMG-CoA reductase by the method.
Measure Pitavastatin Calcium granule prepared by three embodiments to the inhibitory action of HMG-CoA reductase, matching suppresses curve, and obtain half-inhibition concentration (IC50), the positive control drug measured, the IC50 of the embodiment of the present invention the results are shown in Table 2.
table 1 related substance and dissolution test result
As seen from Table 1: Pitavastatin Calcium granule of the present invention, the clear impurity content of the sheet power of comparatively going on the market well below listing sheet power clear it.
table 2 each group of IC to HMG-CoA reductase
50
Table 2 can be found out: Pitavastatin Calcium granule of the present invention, and what sheet power of comparatively going on the market was clear has the activity better suppressing HMG-CoA reductase.
test example 2: embodiment accelerated test and long term test
Accelerated test: according to the requirement of " Chinese Pharmacopoeia version in 2010 " stability test guideline, long term test has been carried out to Pitavastatin Calcium granule of the present invention.By embodiment 2-4 sample commercially available back, be placed in climatic chamber, 40 DEG C ± 2 DEG C, place 6 months under relative humidity 75% ± 5% condition, detect by stability high spot reviews project.
Long term test: according to the requirement of " Chinese Pharmacopoeia version in 2010 " stability test guideline, long term test has been carried out to Pitavastatin Calcium granule of the present invention.By embodiment 2-4 sample commercially available back, be placed in climatic chamber, 25 DEG C ± 2 DEG C, place 24 months under relative humidity 60% ± 10% condition, detect by stability high spot reviews project.
result shows:pitavastatin Calcium granule accelerated test 6 months prepared by embodiment of the present invention 2-4 or long term test are after 24 months, and indices has no significant change, good stability, and impurity content is low.
Claims (5)
1. a blood lipid-lowering medicine Pitavastatin Calcium composition granule, is characterized in that: described composition granule is made up of Pitavastatin Calcium, mannitol, sucrose, tertiary butyl-4-hydroxy methyl phenyl ethers anisole, sodium alginate, purified water, silicon dioxide; Described Pitavastatin Calcium is crystal, and the X-ray powder diffraction pattern that the measurement of use Cu-K alpha ray obtains as shown in Figure 1.
2. blood lipid-lowering medicine Pitavastatin Calcium composition granule according to claim 1, it is characterized in that: with parts by weight, described composition granule is made up of the Pitavastatin Calcium of 0.2 weight portion, the mannitol of 4.3-4.7 weight portion, the sucrose of 14.2-14.6 weight portion, the tertiary butyl-4-hydroxy methyl phenyl ethers anisole of 1.3-1.7 weight portion, the sodium alginate of 1.3-1.7 weight portion, the purified water of 4.3-4.7 weight portion, the silicon dioxide of 0.2-0.4 weight portion.
3. blood lipid-lowering medicine Pitavastatin Calcium composition granule according to claim 2, it is characterized in that: with parts by weight, described composition granule is made up of the Pitavastatin Calcium of 0.2 weight portion, the mannitol of 4.5 weight portions, the sucrose of 14.4 weight portions, the tertiary butyl-4-hydroxy methyl phenyl ethers anisole of 1.5 weight portions, the sodium alginate of 1.5 weight portions, the purified water of 4.5 weight portions, the silicon dioxide of 0.3 weight portion.
4. prepare a method for blood lipid-lowering medicine Pitavastatin Calcium composition granule according to claim 1, it is characterized in that comprising the following steps:
1) weigh according to technology preparation amount;
2) Feedstock treating: by raw material pulverizing 100 mesh sieve;
3) premix: select three-dimensional motion mixer, the mode that the Pitavastatin Calcium of recipe quantity and mannitol equivalent are progressively increased mixed, mixing velocity 12r/min, mixes 5min at every turn;
4) mixing granulation: the sucrose of Pitavastatin Calcium complete for premix and mannitol and recipe quantity, tertiary butyl-4-hydroxy methyl phenyl ethers anisole, sodium alginate are added in wet mixing pelletizer, open stirring motor and be dry mixed 10 minutes, add appropriate purified water, wet mixing cutting 120-150 soft material second, selects 18 order nylon wires to be arranged in oscillating granulator and granulates;
5) drying and screening: regulate boiling drier inlet temperature 50-55 DEG C, wet granular is placed in boiling drier and carries out drying, be dried to moisture < 3.0%, granule shaking screen after drying is sieved the granule got between 16 order-30 orders;
6) always mix: the silicon dioxide of the dry granule after granulate and recipe quantity is joined in mixer, mixing velocity 12r/min, open mixer and mix 30 minutes;
7) pack: granule is joined particles packing machine intermediate package, control content uniformity and meet inner quality standard.
5. blood lipid-lowering medicine Pitavastatin Calcium composition granule according to claim 1, it is characterized in that, the preparation method of the crystal of described Pitavastatin Calcium comprises the following steps:
(1) ground by Pitavastatin Calcium crude product, cross 60 mesh sieves, then joining volume is in the methanol of 6 times of Pitavastatin Calcium weight, and 130 revs/min are stirred 10 minutes;
Add the methanol that volume is 4 times of Pitavastatin Calcium weight under (2) 90 revs/min of stirrings, be warming up to 45 DEG C simultaneously;
(3) after solution adds, leave standstill 4 hours, the volume dripping 0 DEG C under 150 revs/min of conditions stirred is 8 times of ether of Pitavastatin Calcium weight, the mixed solution of chloroform, and the volume ratio of ether, chloroform is at the uniform velocity dropwise in 3:2,2h;
(4) be cooled to-5 DEG C after being added dropwise to complete, continue to stir 2h under the stir speed (S.S.) of 110 revs/min, leave standstill 1h crystallize out, filter, washing, vacuum drying obtains Pitavastatin Calcium crystal.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510589951.1A CN105125504A (en) | 2015-09-17 | 2015-09-17 | Composition granules of blood lipid-lowering drug pitavastatin calcium |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510589951.1A CN105125504A (en) | 2015-09-17 | 2015-09-17 | Composition granules of blood lipid-lowering drug pitavastatin calcium |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105125504A true CN105125504A (en) | 2015-12-09 |
Family
ID=54711333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510589951.1A Withdrawn CN105125504A (en) | 2015-09-17 | 2015-09-17 | Composition granules of blood lipid-lowering drug pitavastatin calcium |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105125504A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1747934A (en) * | 2003-02-12 | 2006-03-15 | 西巴特殊化学品控股有限公司 | Crystalline forms of pitavastatin calcium |
| AU2007235353A1 (en) * | 2006-04-06 | 2007-10-18 | Schering Corporation | Use of combination preparations containing thrombin receptor antagonists for treating cardiovascular disorders |
| US20070264348A1 (en) * | 2002-05-24 | 2007-11-15 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
| CN103012260A (en) * | 2012-10-15 | 2013-04-03 | 武汉市江润精细化工有限责任公司 | Preparation method of pitavastatin calcium intermediate compound |
-
2015
- 2015-09-17 CN CN201510589951.1A patent/CN105125504A/en not_active Withdrawn
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070264348A1 (en) * | 2002-05-24 | 2007-11-15 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
| CN1747934A (en) * | 2003-02-12 | 2006-03-15 | 西巴特殊化学品控股有限公司 | Crystalline forms of pitavastatin calcium |
| AU2007235353A1 (en) * | 2006-04-06 | 2007-10-18 | Schering Corporation | Use of combination preparations containing thrombin receptor antagonists for treating cardiovascular disorders |
| CN103012260A (en) * | 2012-10-15 | 2013-04-03 | 武汉市江润精细化工有限责任公司 | Preparation method of pitavastatin calcium intermediate compound |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104860882A (en) | Drug pitavastatin calcium composition for treating hyperlipidemia | |
| CN104523640A (en) | Ticagrelor tablets and preparation method thereof | |
| CN106698380B (en) | A kind of hydroxyapatite and preparation method thereof using shell preparation | |
| CN106361712A (en) | Glimepiride tablet and preparation method thereof | |
| CN105125504A (en) | Composition granules of blood lipid-lowering drug pitavastatin calcium | |
| CN105125498A (en) | Blood fat reducing drug, namely, pitavastatin calcium composition dry suspension | |
| CN104739789B (en) | Pharmaceutical composition containing Solifenacin or its salt | |
| CN104844506A (en) | Medicinal pitavastatin calcium compound for treating hyperlipidemia | |
| CN105534937A (en) | Cefadroxil tablet and preparation method thereof | |
| CN114288259B (en) | Quick-release preparation of vitamin B2 and preparation method thereof | |
| CN102743369A (en) | N-acetylcysteine pharmaceutical composition and preparation method thereof | |
| CN105213319A (en) | A kind of blood lipid-lowering medicine Pitavastatin calcium composition dry suspension | |
| CN105055417A (en) | Medicine pitavastatin calcium composition capsule for curing hyperlipidemia | |
| CN105434375A (en) | Levetiracetam tablet and preparation method thereof | |
| CN104211693A (en) | Rivaroxaban new crystalline form, preparation method and application | |
| CN103505425A (en) | Stable pitavastatin calcium tablets | |
| CN100341495C (en) | Solid dispersion and preoral combination of glibenclamide and preparation method | |
| CN105106213A (en) | Pitavastatin calcium composition granules with effect of reducing blood fat | |
| CN105106171A (en) | Pitavastatin calcium composition capsules for treating hyperlipidemia | |
| CN104645322A (en) | Phosphoesterases complex enteric-coated tablet and preparation method and application thereof | |
| CN110787139A (en) | Montelukast sodium pharmaceutical composition | |
| CN105055356A (en) | Medicine pitavastatin calcium composition tablet for treating hyperlipidemia | |
| CN103142500B (en) | Sustained-release particle of etoposide | |
| CN104288113A (en) | Azilsartan pharmaceutical composition and preparation method thereof | |
| CN1891256A (en) | Red sage root dispersible tablet for treating cornary heart diseae and its preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20151209 |